Medicaid coverage for nonsteroidal topical atopic dermatitis treatment is often restrictive and variable across the United States

Published: 16 February 2024| Version 1 | DOI: 10.17632/rky67kt6g9.1
Contributors:
Eun Jae Kim,
, John Barbieri,

Description

Supplemental table for study investigating nonsteroidal topical AD medication coverage in the United States under Medicaid plans.

Files

Categories

Ruxolitinib, Atopic Dermatitis, Topical Treatment, Pimecrolimus, Tacrolimus, Health Insurance Coverage

Licence